AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule ...

The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous ...

The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Allogene Therapeutics is undervalued. Read more on ALLO stock's cash runway, innovative CAR-T therapies, and market expansion ...

Sovereign Metals has confirmed that graphite concentrate from its Kasiya project in Malawi is of refractory-grade quality.

Sovereign Metals has confirmed the Kasiya Rutile-Graphite Project’s key features required for use in refractory applications.

In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.

(Alliance News) - Sovereign Metals Ltd on Wednesday said testing has confirmed that graphite from its Kasiya rutile-graphite project in Malawi meets the requirements for use in refractory applications ...